loncastuximab tesirine Zynlonta
Selected indexed studies
- Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. (Lancet Oncol, 2021) [PMID:33989558]
- Loncastuximab Tesirine. (, 2006) [PMID:34014627]
- Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study. (Haematologica, 2024) [PMID:37646659]
_Worker-drafted node — pending editorial review._
Connections
loncastuximab tesirine Zynlonta is a side effect of
Sources
- Loncastuximab Tesirine. (2006) pubmed
- Loncastuximab Tesirine: First Approval. (2021) pubmed
- Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. (2021) pubmed
- Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study. (2024) pubmed
- Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre, single-arm, phase 2 trial. (2025) pubmed
- Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. (2024) pubmed
- Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. (2024) pubmed
- Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. (2024) pubmed
- Global, regional, and national prevalence of adult overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021. (2025) pubmed
- How I treat older patients with relapsed/refractory diffuse large B-cell lymphoma. (2025) pubmed